首页 | 本学科首页   官方微博 | 高级检索  
     


Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study
Authors:Martin?Kropff  author-information"  >  author-information__contact u-icon-before"  >  mailto:martin.kropff@klinikum-os.de"   title="  martin.kropff@klinikum-os.de"   itemprop="  email"   data-track="  click"   data-track-action="  Email author"   data-track-label="  "  >Email author,Martin?Vogel,Guido?Bisping,Rudolf?Schlag,Rudolf?Weide,Wolfgang?Knauf,Heinrich?Fiechtner,Georgi?Kojouharoff,Stephan?Kremers,Wolfgang?E.?Berdel
Affiliation:1.Department of Medicine A,University Hospital Muenster,Muenster,Germany;2.Department of Medicine III, Oncology,Hematology, and Stem Cell Transplantation,Osnabrück,Germany;3.Janssen-Cilag GmbH,Neuss,Germany;4.Private Practice for Hematology/Oncology,Würzburg,Germany;5.Private Practice and Clinic for Hematology/Oncology,Koblenz,Germany;6.Private Practice for Hematology and Oncology,Frankfurt,Germany;7.Private Practice for Hematology, Oncology and Palliative Medicine,Stuttgart,Germany;8.Private Practice for Hematology/Oncology,Darmstadt,Germany;9.Center for Oncology,Lebach,Germany
Abstract:
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号